Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
Gilberto de Lima Lopes Jr., Joel E. Segel, Daniel S. W. Tan, Young K. Do, Tony Mok, Eric A. FinkelsteinVolume:
118
Year:
2012
Language:
english
Pages:
8
DOI:
10.1002/cncr.26372
File:
PDF, 870 KB
english, 2012